Zhong Xi （ Fu Jian ） Yao Ye You Xian Gong Si

Main research purpose: According to the relevant provisions of bioequivalence test, the flurbiprofen gel patch (trade name: Zepusi®, specification: 40mg) with the license holder Mikasa Seiyaku Co., Ltd was selected as the reference preparation, and the test preparation flurbiprofen gel patch (specification: 40mg) produced by Jiangsu Wangao Pharmaceutical Co., Ltd. and provided by Jiangsu Jiming Pharmaceutical Co., Ltd. was subjected to human bioequivalence test under fasting external use conditions, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under external use conditions. Secondary research objectives: 1. Observe the safety of Chinese healthy subjects after external use of the test preparation flurbiprofen gel patch (specification: 40mg) and the reference preparation flurbiprofen gel patch (trade name: Zepusi®, specification: 40mg). 2. To evaluate the adhesion and external irritation of the test preparation flurbiprofen gel patch (specification: 40 mg) or the reference preparation flurbiprofen gel patch (trade name: Zepus®, specification: 40 mg) applied externally to healthy volunteers during the trial.

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of trazodone hydrochloride extended-release tablets (specification: 150 mg, applicant: Zhongxi (Fujian) Pharmaceutical Co., Ltd.) and the reference formulation (trade name: TRITTICO®, specification: 150 mg, licensee: AZ. CHIM.RIUN. ANGELINI FRANCESCO ACRAF S.P.A.) after a single oral dose under fasting and postprandial conditions in healthy Chinese adult subjects. Secondary study objectives To study the safety of the test formulation of trazodone hydrochloride extended-release tablets (specification: 150 mg) and the reference formulation (trade name: TRITTICO®, specification: 150 mg) in healthy Chinese adult subjects.

The reference preparation was vonoprazan fumarate tablets (trade name: Vocinti®/Walker®, specification: 20 mg) licensed by Takeda Pharmaceutical Company Limited, and the test preparation was vonoprazan fumarate tablets (specification: 20 mg) licensed by Zhongxi (Fujian) Pharmaceutical Co., Ltd. The bioequivalence of the two preparations in Chinese healthy adult subjects in the fasting/postprandial state was evaluated. At the same time, the safety of the test preparation and the reference preparation in Chinese healthy adult subjects in the fasting/postprandial state was evaluated.